Takeda’s Velcade Patent Overturned in Win for Generics

Updated on

Takeda Pharmaceutical Co. lost a court ruling that could shave years off the time before generic-drug versions of its top-selling cancer drug Velcade hits the market.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.